Core Insights - The baking enzyme preparation industry in China is experiencing rapid growth driven by the expanding market for baked goods and increasing consumer demand for healthy, functional products, particularly low-sugar and high-fiber options [1][14] - The market size of China's baking enzyme preparation industry is projected to reach approximately 2.15 billion yuan in 2024, with a year-on-year growth of 15%, and is expected to further grow to 2.48 billion yuan by 2025 [14] - The industry is characterized by a complete supply chain, including upstream raw material supply, midstream production, and downstream applications, with significant advancements in technology and product innovation [6][12] Industry Overview - Baking enzyme preparations are natural protein catalysts extracted through biotechnology, aimed at improving the quality, processing performance, and nutritional value of baked goods [2][3] - These enzymes enhance dough extensibility, fermentation efficiency, delay aging, and optimize texture by breaking down components such as starch, protein, or cellulose [2][3] - The main types of baking enzymes include amylases, proteases, xylanases, lipases, and glucose oxidases, sourced from microorganisms or plants, known for their efficiency and safety [2][3] Market Dynamics - The retail market for baked goods in China is expected to reach 611.07 billion yuan in 2024, growing at a rate of 8.8%, with health-oriented and scenario-based products becoming new consumer hotspots [8] - The number of baking stores in China is projected to increase from 285,000 in 2020 to 338,000 by 2025, although the annual growth rate has slowed from 5.6% to 0.6% [10] - The enzyme preparation industry is expected to produce 2.074 million tons in 2024, reflecting a year-on-year growth of 7.5%, with food industry applications maintaining a 42.3% market share [12][14] Competitive Landscape - The baking enzyme preparation industry in China is characterized by a competitive landscape where international giants dominate the high-end market, while domestic companies are rapidly catching up [18][20] - Major international brands like Novozymes and Genencor lead the high-end market, while domestic firms such as Yidoli and Blue Biological are making strides in basic enzyme products and gradually moving into high-end fields [18][20] - The market concentration is increasing, with the East China region accounting for over 60% of the market share, driven by technological advancements and economies of scale [18][20] Development Trends - The industry is evolving towards high-end technology, health sustainability, and global market integration, with innovations in biotechnology driving the development of efficient and stable enzyme preparations [23][24] - There is a growing demand for functional enzyme preparations that cater to health-conscious consumers, with a shift towards low-sensitivity and high-fiber products [24] - The domestic market is expanding, particularly in the eastern regions, while companies are also establishing production facilities in Southeast Asia to leverage local resources and reduce costs [25]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-029 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 单位：万元 | 担保人 | 被担保人 | 本次担保 | 担保余额 | 担保余额占公司 2024 年 | | --- | --- | --- | --- | --- | | | | 金额 | （含本次） | 经审计净资产的比例 | | 青岛蔚蓝生物股份有限 | 青岛蔚蓝动物保健集团 | 1,000.00 | 2,990.00 | 1.72% | | 公司 | 有限公司 | | | | 一、 担保情况概述 （一）担保基本情况 2025 年 6 月 26 日，青岛蔚蓝生物股份有限公司（以下简称"公司"）与中 国光大银行股份有限公司青岛城阳支行签署了《最高额保证合同》，为公司全资 子公司蔚蓝动保在该行开展的授信业务提供连带责任保证担保，担保总额为人民 币 1,000.00 万元。 截至本公告日，公司对资产负债率为 70%以下的控股子公司的可 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-028 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：青岛蔚蓝动物保健集团有限公司（以下简称"蔚蓝动保"）、 青岛康地恩动物药业有限公司（以下简称"动物药业"） 本次担保金额及已实际为其提供的担保余额： 本次担保是否有反担保：无 对外担保逾期的累计数量：无 一、 担保情况概述 （一）担保基本情况 1、2025 年 6 月 26 日，青岛蔚蓝生物股份有限公司（以下简称"公司"）与 兴业银行股份有限公司青岛分行签署了《最高额保证合同》，为公司全资子公司 蔚蓝动保在该行开展的授信业务提供连带责任保证担保，担保总额为人民币 1,000.00 万元。 2、2025 年 6 月 26 日，公司与兴业银行股份有限公司青岛分行签署了《最 高额保证合同》，为公司全资子公司动物药业在该行开展的授信业务提供连带责 任保证担保，担保总额为人民币 1,000.00 万元。 单位：万元 单位：万元 ...

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-027 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛动 保国家工程技术研究中心有限公司、青岛蔚蓝动物保健集团有限公司与其他单位 联合申报的"猪伪狂犬病病毒基因缺失灭活疫苗（CY-6 株）"为三类新兽药；批 准公司及全资子公司青岛动保国家工程技术研究中心有限公司、青岛蔚蓝动物保 健集团有限公司与其他单位联合申报的"鸡新城疫、禽流感（H9 亚型）、禽腺病 毒病（I 群 4 型）三联灭活疫苗（La Sota 株+TA 株+LC 株）"为三类新兽药，并 于近日核发了《新兽药注册证书》（农业农村部公告第 920 号）。 一、新兽药的基本信息 1、猪伪狂犬病病毒基因缺失灭活疫苗（CY-6 株） 新兽药名称：猪伪狂犬病病毒基因缺失灭活疫苗（CY-6 株） 2、鸡新城疫、禽流感（H9 亚型） ...

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has obtained a new veterinary drug registration certificate for "Prednisolone Tablets," marking a significant advancement in the treatment of canine allergic and inflammatory diseases [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug, "Prednisolone Tablets," is classified as a Category V new veterinary drug and is approved for treating allergic and inflammatory diseases in dogs, including non-specific eczema, summer dermatitis, and allergic conditions [2][3]. - The drug is developed by a consortium of companies, including Qingdao Weilan Biological Co., Ltd. and its subsidiaries, with a total research and development investment of 1.7444 million yuan [2][3]. Group 2: Market Background - Skin diseases have the highest incidence among pet diseases, particularly in dogs, with recurrent skin conditions accounting for over 75% of total incidence rates [2][3]. - There is a limited variety of drugs available for treating inflammatory skin diseases in pets, primarily relying on glucocorticoids, which have significant side effects and metabolic burdens [3][4]. Group 3: Drug Development and Impact - Prednisolone is a modified glucocorticoid with four times the anti-inflammatory activity of hydrocortisone and reduced sodium retention, making it suitable for animals with liver dysfunction [3][4]. - The approval of the new veterinary drug reflects the company's commitment to technological innovation and is expected to create new growth opportunities for the business [4].

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-026 新兽药名称：泼尼松龙片 研制单位：青岛蔚蓝至宠生物科技有限公司、青岛蔚蓝生物股份有限公司、 江西瑞德制药有限公司、青岛康地恩动物药业有限公司、泰州博莱得利生物科技 有限公司、上海信元动物药品有限公司、四川吉星动物药业有限公司、青岛动保 国家工程技术研究中心有限公司、河北远征禾木药业有限公司、江苏恒丰强生物 技术有限公司。 新兽药注册证书号：（2025）新兽药证字 56 号 监测期：3 年 注册分类：五类 主要成分：泼尼松龙 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛蔚 蓝至宠生物科技有限公司、青岛康地恩动物药业有限公司、青岛动保国家工程技 术研究中心有限公司与其他单位联合申报的"泼尼松龙片"为五类新兽药，并于 近日核发了《新兽药注册证书》（农业农村部公告第 917 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-025 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：青岛蔚蓝生物集团有限公司（以下简称"蔚蓝生物集团"）、 青岛康地恩动物药业有限公司（以下简称"动物药业"） 本次担保金额及已实际为其提供的担保余额： 本次担保是否有反担保：无 对外担保逾期的累计数量：无 单位：万元 单位：万元 担保人 被担保人 本次担保 金额 担保余额 （含本次） 担保余额占公司 2024 年 经审计净资产的比例 青岛蔚蓝生物股份有限 公司 青岛蔚蓝生物集团有限 公司 5,400.00 22,673.07 13.05% 青岛蔚蓝生物股份有限 公司 青岛康地恩动物药业有 限公司 2,000.00 4,013.83 2.31% | 担保人 | 被担保人 | 本次担保 | 担保余额 | 担保余额占公司 2024 年 | | --- | --- | --- | --- | --- | | | | 金额 | （ ...

Summary of Key Points Core Viewpoint - The announcement details the provision of a guarantee by Qingdao Weilan Biological Co., Ltd. for its subsidiary, Qingdao Weilan Longchu Biotechnology Co., Ltd., to support its credit activities with a total guarantee amount of RMB 178,950.00 million for the fiscal year 2025 [1][2]. Group 1: Guarantee Overview - The guaranteed entity is Qingdao Weilan Longchu Biotechnology Co., Ltd. [1] - The total guarantee amount provided is RMB 178,950.00 million, with the current balance being reported [2]. - The guarantee does not have any counter-guarantee [1]. - There are no overdue guarantees reported [1]. Group 2: Approval Process - The guarantee was approved by the company's board meeting on April 25, 2025, and subsequently by the annual shareholders' meeting on May 16, 2025 [2]. - The details of the guarantee were disclosed in announcements on April 26, 2025, and May 17, 2025 [2]. Group 3: Financial Status of the Guaranteed Entity - Qingdao Weilan Longchu Biotechnology Co., Ltd. was established on August 11, 2011, with a registered capital of RMB 33.50 million [3]. - The total assets of the company are reported at RMB 79,627.70 million, with total liabilities at RMB 41,997.90 million, resulting in net assets of RMB 37,629.80 million [4]. - The company's revenue for the audited period is RMB 83,549.20 million, with a net profit of RMB 4,286.00 million [4]. Group 4: External Guarantee Status - The total amount of external guarantees provided by the company and its subsidiaries is RMB 91,420.00 million, which constitutes 52.61% of the net assets attributable to shareholders as of December 31, 2024 [4][5]. - There are no overdue guarantees as of the announcement date [5].